We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The number of drugs approved to treat rare diseases has increased significantly over the past 10 years, according to a report issued April 20 by PhRMA, the National Organization for Rare Disorders and the Genetic Alliance.
PhRMA has named an independent direct-to-consumer (DTC) ad review panel April 27 in an effort to address healthcare providers’ concerns with such ads, PhRMA President Billy Tauzin said.
Manufacturers of 193 brand-name prescription drugs widely used by mostly older Americans raised the price they charge wholesalers and other direct purchasers more than the general inflation rate for the sixth year in a row, AARP said in a report released April 10.
PhRMA has asked the Office of the U.S. Trade Representative (USTR) to block Israel’s bid to join the Organization of Economic Cooperation and Development (OECD) on grounds the country does not provide sufficient intellectual property protection for U.S. pharmaceutical companies operating in Israel.
A Senate panel overseeing federal drug programs has expanded its investigation into whether the “educational grants” drugmakers give to states and healthcare organizations are more focused on marketing than education.
Drug industry representatives have expressed reservations about the FDA's proposed plan to raise user fees to pay for certain activities that are not directly related to product application review.
PhRMA’s recently approved code of conduct for direct-to-consumer (DTC) advertising is a step in the right direction for the drug industry, according to the head of the FDA’s drug advertising oversight arm.
Retail prices for frequently used brand drugs have increased roughly three times faster than those of commonly used generic drugs, according to a Government Accountability Office (GAO) report, which predicts public and private insurers will turn to generics to reduce costs.